Gritstone Oncology Inc. Stock News

Their growth prospects are massive.

EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immuno

Does Gritstone bio Inc. (GRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immuno

Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunot

Coronavirus players may deliver strong returns well into the future.

EMERYVILLE, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunot

Gritstone has pivoted from being a cancer vaccine player to a coronavirus vaccine company. That news took the stock up 5x in January.

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the s

Immunocore: 'Off-The-Shelf' T Cell Therapy

– Preliminary Data from Phase 1 Study of CORAL Expected Mid-year –

Why? They're focusing on one of the biggest coronavirus problems.

They're off to a good start.

Here's why these highfliers could have more fuel in the tank.